MetaVia Presents New Phase 1 Data on DA-1726, Weight Loss of 9.1%

MetaVia announced the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin - OXM - analog agonist targeting glucagon-like peptide-1 receptors, or GLP1R, and glucagon receptors, or GCGR, at the European Association for the Study of the Liver Congress 2026 held May 27-30 in Barcelona. The data highlighted favorable safety and tolerability, clinically meaningful reductions in body weight and waist circumference at the 48 mg dose without titration, and exploratory, noninvasive liver-related findings supporting continued evaluation in metabolic dysfunction-associated steatohepatitis, or MASH. DA-1726 demonstrated progressive weight loss up to 9.1% at the 48 mg dose level without evidence of plateau, while maintaining favorable tolerability even in the absence of dose titration. Exploratory FibroScan findings demonstrated early and consistent improvements across multiple noninvasive liver biomarkers, including liver stiffness, CAP and FAST scores, illustrating the potential of DA-1726 in obesity and MASH, where metabolic and hepatic dysfunction are closely linked. Based on these findings, MetaVia continues to advance the ongoing Phase 1 Part 3a/3b titration studies designed to evaluate longer-term dosing strategies, optimize tolerability at higher exposures, and further assess durability of metabolic and liver-related effects. DA-1726 was generally well tolerated up to the 48 mg dose level, with no serious adverse events or treatment-related discontinuations observed. No clinically meaningful changes in cardiovascular parameters were observed. Participants achieved a mean body-weight reduction of 6.1% at Day 26 and 9.1% at Day 54, with no evidence of a plateau through Week 8. Waist circumference was reduced by 5.8 cm at Day 26 and 9.8 cm at Day 54. Liver-related improvements support further long-term evaluation of DA-1726 in obesity-associated liver disease and MASH.